Skip to content
Inciteful Med

Diagnosis and Specialized Imaging

Last updated:

Endocrine tumors are diagnosed using a combination of biochemical blood and urine tests to measure hormone levels, alongside specialized imaging like Ga-68 DOTATATE PET/CT scans. For certain adrenal tumors, these non-invasive tests are used instead of a biopsy, which can be dangerous.

Key Takeaways

  • • Biochemical testing of blood and urine helps detect biomarkers like Chromogranin A and metanephrines that are produced by endocrine tumors.
  • • A specialized Ga-68 DOTATATE PET/CT scan can locate tiny neuroendocrine tumors that standard CT or MRI scans might miss.
  • • Biopsies of adrenal or abdominal masses can be life-threatening if the tumor is an adrenaline-producing pheochromocytoma.
  • • Patients may need to pause certain medications like PPIs or avoid specific foods to prevent false positive results on diagnostic biomarker tests.

Diagnosing an endocrine tumor is like solving a puzzle with two main types of pieces: biochemical (what the cells are producing) and anatomical/functional (where the cells are and how they behave). To get a complete picture, your medical team must look at both your bloodwork and your scans [1][2][3].

Biochemical Testing: The “Liquid Biopsy”

Before any imaging or invasive procedures, doctors often start with blood and urine tests. These tests look for biomarkers—substances produced by tumor cells that circulate in your body [4][5].

  • Chromogranin A (CgA): A common protein marker released by many neuroendocrine tumors. It is often used to track tumor burden and response to treatment [4][6]. Note: Common acid-reflux medications (Proton Pump Inhibitors or PPIs) can falsely elevate CgA levels. Ask your doctor if you need to pause these before a blood draw.
  • Metanephrines: These are breakdown products of adrenaline. Testing for metanephrines in your plasma (blood) or a 24-hour urine sample is the “gold standard” for identifying adrenal tumors like pheochromocytomas [1][7].
  • 5-HIAA: This is a byproduct of serotonin. If you have symptoms of carcinoid syndrome (like flushing or diarrhea), doctors will measure 5-HIAA in your urine or blood [8][9]. You will need to follow a strict diet avoiding serotonin-rich foods (such as bananas, avocados, and walnuts) before and during the collection to prevent false positives.
  • Hormone Panels: Depending on your symptoms, you may also have tests for cortisol (Cushing’s), PTH and calcium (parathyroid), or insulin and glucose (pancreas) [1][10].

Specialized Imaging: Seeing Beyond the Structure

While standard CT and MRI scans provide excellent “anatomical” detail (the size and shape of a tumor), they sometimes miss very small tumors or cannot tell if a mass is active [11][12].

Ga-68 DOTATATE PET/CT: The New Gold Standard for NETs

For specific neuroendocrine tumors (NETs), particularly those of the gastrointestinal tract and pancreas, a specialized scan called a Ga-68 DOTATATE PET/CT is significantly more sensitive than standard imaging [11][13]. (Note: This scan is specifically used for these SSTR-expressing tumors, and is not typical for general thyroid or pituitary tumors).

  • How it works: Many NET cells have “docking stations” on their surface called somatostatin receptors (SSTRs). In this scan, a small amount of a radioactive tracer (the DOTATATE) is injected. It travels through your body and “plugs into” these receptors, making even tiny clusters of tumor cells glow brightly on the PET scan [13][14].
  • Why it matters: This scan can find tumors that standard CT scans miss, often changing the treatment plan for 35% to 50% of patients [15][16][17].

When a Biopsy Is Risky

In most cancers, a biopsy (taking a small tissue sample) is the first step. However, with certain endocrine tumors, a biopsy can be dangerous or unnecessary:

  • The Pheochromocytoma Rule: If a tumor is a pheochromocytoma (an adrenaline-producing adrenal tumor), sticking a needle into it can cause a massive release of hormones, leading to a life-threatening hypertensive crisis (a sudden, dangerous spike in blood pressure) [18][19].
  • Biochemical Proof: In many cases, if your blood/urine tests are positive and your specialized PET scan (like DOTATATE) is also positive, the diagnosis is clear enough that a biopsy is not needed before moving straight to treatment or surgery [20][21].

Important: Never undergo a biopsy of an adrenal or abdominal mass until your doctors have officially ruled out a pheochromocytoma with biochemical testing [20][22].

Frequently Asked Questions

Why is a biopsy sometimes dangerous for endocrine tumors?
For adrenaline-producing tumors called pheochromocytomas, inserting a needle for a biopsy can cause a massive release of hormones. This sudden surge can lead to a life-threatening spike in blood pressure known as a hypertensive crisis. Doctors often rely on blood tests and specific scans instead of biopsies to confirm the diagnosis.
What is a Ga-68 DOTATATE PET/CT scan used for?
This specialized scan is used to find specific neuroendocrine tumors, particularly in the gastrointestinal tract and pancreas. It uses a radioactive tracer that attaches to somatostatin receptors on the surface of tumor cells, making even tiny, hard-to-find tumors glow brightly on the image.
Do I need to change my diet before a 5-HIAA urine test?
Yes, you will need to follow a strict diet and avoid serotonin-rich foods like bananas, avocados, and walnuts before and during your urine collection. Eating these foods can cause a falsely high 5-HIAA result, which is a key marker used to test for carcinoid syndrome.
How do doctors know if an endocrine tumor is active?
Doctors use biochemical testing of your blood and urine to look for specific biomarkers like Chromogranin A, metanephrines, or elevated hormones. These tests, sometimes called liquid biopsies, reveal what substances the tumor cells are actively producing and releasing into your body.

Questions for Your Doctor

  • • Before we consider a biopsy, have we ruled out a pheochromocytoma with metanephrine testing?
  • • Will a Ga-68 DOTATATE PET/CT scan provide more information than my standard CT or MRI for my specific type of tumor?
  • • Which specific 'functional' biomarkers, like Chromogranin A or 5-HIAA, are we monitoring in my blood or urine?
  • • Do I need to pause any medications (like PPIs) or change my diet before my biomarker tests?
  • • Is my tumor 'SSTR-positive,' and does that make me a candidate for targeted therapies like PRRT?
  • • If my tumor is 'non-functioning,' what biomarkers will we use to track its activity over time?

Questions for You

  • • Have I had a 24-hour urine collection or a special blood test to check my hormone levels?
  • • Am I experiencing 'spells' of high blood pressure, sweating, or heart palpitations that might suggest a secreting tumor?
  • • Do I have copies of both my radiology reports (imaging) and my lab results (biochemistry) for my own records?
  • • Was my tumor found 'incidentally' during a scan for a different health concern?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.

    Pavel ME, Phan AT, Wolin EM, et al.

    The oncologist 2019; (24(4)):463-474 doi:10.1634/theoncologist.2018-0217.

    PMID: 30355775
  2. 2

    Urinary steroid metabolites in a case of florid Ectopic Cushing's syndrome and clinical correlations.

    Kyriacou A, Stepien KM, Issa B

    Hormones (Athens, Greece) 2016; (15(4)):540-547 doi:10.14310/horm.2002.1695.

    PMID: 28222414
  3. 3

    The Pancreatic Endocrine Tumors - Experience of First Surgical Clinic Iasi.

    Târcoveanu E, Lupascu C, Vasilescu A, et al.

    Chirurgia (Bucharest, Romania : 1990) 2019; (114(5)):639-649.

    PMID: 31670640
  4. 4

    Gastrointestinal neuroendocrine tumors in 2020.

    Ahmed M

    World journal of gastrointestinal oncology 2020; (12(8)):791-807 doi:10.4251/wjgo.v12.i8.791.

    PMID: 32879660
  5. 5

    Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls.

    Gut P, Czarnywojtek A, Fischbach J, et al.

    Archives of medical science : AMS 2016; (12(1)):1-9 doi:10.5114/aoms.2016.57577.

    PMID: 26925113
  6. 6

    BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.

    Mirakhur B, Pavel ME, Pommier RF, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2018; doi:10.4158/EP-2018-0296.

    PMID: 30084687
  7. 7

    Analysis of Urinary Metanephrines Using Liquid Chromatography Tandem Mass Spectrometry.

    Thaitumu MN, Frank EL

    Methods in molecular biology (Clifton, N.J.) 2025; (2891()):257-268 doi:10.1007/978-1-0716-4334-1_14.

    PMID: 39812987
  8. 8

    Plasma tryptophan pathway metabolites quantified by liquid chromatography-tandem mass spectrometry as biomarkers in neuroendocrine tumor patients.

    Johansen SU, Hansen T, Nordborg A, et al.

    Journal of neuroendocrinology 2024; (36(3)):e13372 doi:10.1111/jne.13372.

    PMID: 38361341
  9. 9

    Serum 5-Hydroxyindoleacetic Acid Measurements for the Diagnosis and Follow-up of Carcinoid Syndrome.

    Kerolles M, Mulders MCF, Mirzaian M, et al.

    The Journal of clinical endocrinology and metabolism 2025; (110(12)):e3980-e3988 doi:10.1210/clinem/dgaf263.

    PMID: 40314148
  10. 10

    Primary hyperparathyroidism due to a giant parathyroid adenoma presenting with pathological fractures and multiple brown tumors.

    Meng J, Aboznadah WM, Pusztaszeri M, Larouche V

    Endocrinology, diabetes & metabolism case reports 2024; (2024(4)).

    PMID: 39700332
  11. 11

    Diagnostic fficiency of 68Ga-DOTATATE PET/CT as ompared to 99mTc-Octreotide SPECT/CT andonventional orphologic odalities in euroendocrine umors.

    Fallahi B, Manafi-Farid R, Eftekhari M, et al.

    Asia Oceania journal of nuclear medicine & biology 2019; (7(2)):129-140 doi:10.22038/AOJNMB.2019.39392.1263.

    PMID: 31380452
  12. 12

    Gallium-68-dotatate PET/CT is better than CT in the management of somatostatin expressing tumors: First experience in Africa.

    Lawal IO, Ololade KO, Lengana T, et al.

    Hellenic journal of nuclear medicine 2017; (20(2)):128-133 doi:10.1967/s002449910553.

    PMID: 28697189
  13. 13

    Molecular and Anatomic Imaging of Neuroendocrine Tumors.

    Szidonya L, Park EA, Kwak JJ, Mallak N

    Surgical oncology clinics of North America 2022; (31(4)):649-671 doi:10.1016/j.soc.2022.06.009.

    PMID: 36243499
  14. 14

    The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors.

    Tirosh A, Kebebew E

    Future oncology (London, England) 2018; (14(2)):111-122 doi:10.2217/fon-2017-0393.

    PMID: 29072093
  15. 15

    Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.

    Crown A, Rocha FG, Raghu P, et al.

    Journal of surgical oncology 2020; (121(3)):480-485 doi:10.1002/jso.25812.

    PMID: 31853990
  16. 16

    Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented.

    Calais J, Czernin J, Eiber M, et al.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017; (58(11)):1793-1796 doi:10.2967/jnumed.117.192450.

    PMID: 28473600
  17. 17

    A Reassessment of the Clinical Utility of 68Ga-DOTATATE PET/CT in Patients With Gastroenteropancreatic Neuroendocrine Tumors.

    Prela O, Caveney B, Strawderman M, et al.

    Journal of surgical oncology 2025; (131(7)):1336-1342 doi:10.1002/jso.28061.

    PMID: 39757730
  18. 18

    Pheochromocytoma presenting as a pancreatic mass: Avoiding a dangerous pitfall in endoscopic ultrasound-guided fine needle aspiration biopsy using GATA3 immunostain.

    Kebe Radulović M, Strojan Fležar M

    Cytopathology : official journal of the British Society for Clinical Cytology 2022; (33(1)):127-131 doi:10.1111/cyt.13060.

    PMID: 34590371
  19. 19

    ANESTHETIC MANAGEMENT IN UNEXPECTED EXTRA- ADRENAL PHEOCROMOCYTOMA PRESENTING WITH THORACIC SPINAL CORD COMPRESSION.

    El Kouny A, Al Harbi M, Arif RM, et al.

    Middle East journal of anaesthesiology 2016; (23(4)):485-9.

    PMID: 27382822
  20. 20

    The Perioperative Biochemical and Clinical Considerations of Pheochromocytoma Management.

    Gombert AJ, Nerantzinis AM, Li J, et al.

    International journal of molecular sciences 2025; (26(13)) doi:10.3390/ijms26136080.

    PMID: 40649858
  21. 21

    Hereditary paraganglioma presenting with atypical symptoms: Case report.

    Eguchi S, Ono R, Sato T, et al.

    Medicine 2021; (100(46)):e27888 doi:10.1097/MD.0000000000027888.

    PMID: 34797335
  22. 22

    Concurrent primary hyperparathyroidism and pheochromocytoma in a Chinese lady with neurofibromatosis type 1.

    Wong CL, Fok CK, Tam VH

    Endocrinology, diabetes & metabolism case reports 2018; (2018()) doi:10.1530/EDM-18-0006.

    PMID: 29623209

This page explains diagnostic testing for endocrine tumors for educational purposes. Always consult your endocrinologist or oncologist to determine which specific diagnostic tests and scans are appropriate and safe for your unique situation.

Stay up to date

Get notified when new research about Tumor of endocrine glands is published.

No spam. Unsubscribe anytime.